Alex Guminski

[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

Michael S. Hofman, Louise Emmett, Shahneen Sandhu et al. · The Lancet · 2021 · 1.1K citations

Medicine, Oncology, Pharmacology +12

Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma

Jenny Lee, Georgina V. Long, Stephanie Boyd et al. · Annals of Oncology · 2017 · 328 citations · Full text

Medicine, Immunology, Oncology +16

Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial

Michael S. Hofman, Louise Emmett, Shahneen Sandhu et al. · The Lancet Oncology · 2023 · 199 citations

Medicine, Oncology, Pharmacology +16

Results of a Prospective Phase 2 Pilot Trial of 177Lu–PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression

Louise Emmett, Megan Crumbaker, Bao Ho et al. · Clinical Genitourinary Cancer · 2018 · 184 citations

Medicine, Oncology, Urology +17

Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer

Stephan B. Dreyer, Rosanna Upstill‐Goddard, Viola Paulus-Hock et al. · Gastroenterology · 2020 · 173 citations · Full text

Life Sciences, Molecular Biology, Oncology +17